(Q43662185)

25 November 2017

title

Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? (English)

1 reference

25 November 2017

0 references

Bosi E

1

1 reference

25 November 2017

Minelli R

series ordinal

2

1 reference

25 November 2017

Bazzigaluppi E

series ordinal

3

1 reference

25 November 2017

Salvi M

series ordinal

4

1 reference

25 November 2017

publication date

1 April 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

18

1 reference

25 November 2017

issue

4

1 reference

25 November 2017

page(s)

329-332

1 reference

Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00492.X

Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00492.X

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00492.X

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00492.X

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00492.X

Reversible diabetes in patient with AIDS-related Kaposi's sarcoma treated with interferon α-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00492.X

10.1046/J.1464-5491.2001.00492.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference